ѻý

Dementia and Terminal Lucidity; Neuropathy After COVID; FDA Sets Donanemab Meeting

<ѻý class="mpt-content-deck">— News and commentary from the world of neurology and neuroscience
MedpageToday
Neuro Break over a computer rendering of neurons.

Why do some people with dementia experience a before death? (The Conversation)

Clinicians should outline like brain volume loss associated with anti-amyloid drugs when counseling Alzheimer's patients considering treatment, researchers said. (JAMA)

The protein FLVCR2 appeared to be a that's responsible for most choline uptake into the brain. (Nature)

New-onset small fiber infection was responsive to treatment with intravenous immune globulin (IVIG), a case-control analysis showed. (Neurology)

Intravenous and potentially effective in improving neurologic outcome of people in a coma after cardiac arrest. (JAMA Neurology)

Repetitive and increased functional connectivity between the hippocampus and precuneus in people with early Alzheimer's disease, a small trial in Korea found. (JAMA Network Open)

Using 7-Tesla resting-state functional MRI data from the Human Connectome Project, researchers mapped a subcortical brain network that may in human consciousness. (Science Translational Medicine)

The FDA scheduled a June 10 advisory committee meeting to discuss for early symptomatic Alzheimer's disease, Eli Lilly said.

Focal often were missed in the emergency department, a small study showed. (Neurology)

Medtronic said it received FDA approval for its Inceptiv to treat chronic pain.

The published a manager's guide to long COVID at work.

  • Judy George covers neurology and neuroscience news for ѻý, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more.